

Effect of green tea extract microencapsulation on hypertriglyceridemia and cardiovascular tissues in high fructose-fed rats

Moon Hee Jung¹, Pil Nam Seong², Myung Hwan Kim³, Na-Hye Myong⁴ and Moon-Jeong Chang^{1§}

¹Department of Food and Nutrition, Kookmin University, 861-1 Chongneung-dong, Sungbuk-gu, Seoul 136-702, Korea

²National Institute of Animal Science, Rural Development Administration, Suwon, Gyeonggi 441-707, Korea

³Department of Food Engineering, Dankook University, Cheonan, Chungnam 330-714, Korea

⁴Department of Pathology, College of Medicine, Dankook University, Cheonan, Chungnam 330-714, Korea

Abstract

The application of polyphenols has attracted great interest in the field of functional foods and nutraceuticals due to their potential health benefits in humans. However, the effectiveness of polyphenols depends on their bioactivity and bioavailability. In the present study, the bioactive component from green tea extract (GTE) was administered orally (50 mg/kg body weight/day) as free or in a microencapsulated form with maltodextrin in rats fed a high fructose diet. High fructose diet induced features of metabolic syndrome including hypertriglyceridemia, hyperuricemia, increased serum total cholesterol, and retroperitoneal obesity. In addition, myocardial fibrosis was increased. In rats receiving high fructose diet, the lowering of blood triglycerides, total cholesterol, non esterified fatty acid (NEFA) and uric acid, as well as the reduction in final body weight and retroperitoneal fat weight associated with the administration of GTE, led to a reversal of the features of metabolic syndrome ($P < 0.05$). In particular, the administration of microencapsulated GTE decreased myocardial fibrosis and increased liver catalase activity consistent with a further alleviation of serum NEFA, and hyperuricemia compared to administration of GTE. Taken together, our results suggest that microencapsulation of the bioactive components of GTE might have a protective effect on cardiovascular system by attenuating the adverse features of myocardial fibrosis, decreasing uric acid levels and increasing hepatic catalase activity effectively by protecting their bioactivities.

Key Words: Microencapsulation, green tea extract, hypertriglyceridemia, myocardial fibrosis

Introduction

Metabolic syndrome (MetS) increases cardiovascular morbidity and mortality and all-cause mortality [1]. The MetS is characterized by a constellation of interrelated metabolic risk factors that appear to induce the development of cardiovascular disease (CVD) [2]. The diagnosis of MetS is made based on the following clinical signs: central obesity, hyperglycemia, hypertension, and atherogenic dyslipidemia [3]. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated triglyceride (TG) and apolipoprotein B and a reduced level of HDL cholesterol (HDL-C). Individuals with these characteristics commonly manifest a proinflammatory state [4]. Past prospective studies have shown an association between TG levels and coronary artery disease [5], and this association remained statistically significant after controlling for HDL-C and other risk factors [6]. More recent epidemiologic studies have reported that plasma TG and LDL particle size predicted subsequent coronary artery disease in 3 different Caucasian populations [7-9].

The primary goal of clinical management in individuals with

MetS is to reduce the risk factors for clinical atherosclerotic disease. Because atherogenic dyslipidemia consists of abnormal levels of TG, small LDL particles, and reduced HDL-C, this condition can become a target for lipid-lowering therapy [3].

Recently, many vegetables, fruits, and herbs have been identified as protective agents against commonly occurring diseases. Epidemiological evidence suggests that high consumption of fruit and vegetables is associated with a reduced risk of cancer CVD [10,11]. These food products contain antioxidants, phenols, and reactive groups with protective properties [12]. Much of the supporting evidence for a preventive effect of polyphenols in various diseases is based on the finding that they facilitate both the scavenging of free radicals with concomitant formation of fairly stable radicals, and the chelation of transition metals, including iron [13,14]. A large number of studies suggest that these compounds have immunomodulatory and anti-inflammatory effects [15]. Therefore, there is a strong demand for natural bioactives obtained from plants.

Previous studies have shown that the bioactivity of functional food ingredients was significantly affected during processing and

This research was supported by a grant from Rural Development Administration (project No. PJ907122052012).

§ **Corresponding Author:** Moon Jeong, Chang, Tel. 82-2-910-4776, Fax. 82-2-910-5249, Email. cmoon@kookmin.ac.kr

Received: May 22, 2013, Revised: June 11, 2013, Accepted: June 11, 2013

©2013 The Korean Nutrition Society and the Korean Society of Community Nutrition

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

storage [16]. Kumamoto *et al.* [17] reported that Copper (II) ion increased the antioxidative activity of catechins in tea extract, but iron (II) ion largely inhibited them. Chen *et al.* [18] found that green tea contained 8 to 15 g of catechins in 100 g of dry leaves, whereas canned tea drink contained only 0.3-35 mg of total catechins per 100 mL. They suggested that the thermal degradation of catechins in various teas during processing, and loss of catechins during storage may occur. Factors that affect the stability of phenolic compounds include structure and concentration, pH, temperature, light, presence of co-ingredients, self-association, sugar and their degradation products, proteins, and sulfur dioxide [19,20]. In addition, the delivery of bioactive ingredients is challenging because of their limited solubility in water and off-odor.

Microencapsulation has been used for the preservation of natural components by entrapping the active ingredient in coating material [21,22]. Encapsulation involves formulating an active ingredient with secondary materials and preparation of a capsule that isolates the active ingredient from the environment until its release upon exposure to a desired stimulus [23]. Ersus and Yrudagel reported that microencapsulation using maltodextrin as the coating material gave the highest anthocyanin content at the end of the drying process [22]. Augustin *et al.* [24] reported that the microencapsulation of a bioactive mixture of fish oil, tributyrin, and resveratrol increased its bioavailability in the gastrointestinal tract and tissue distribution.

Although consumers are increasingly aware of the diet-related health benefits, a large group of the population lacks an adequate intake of fruits and vegetables. Thus, a dietary supplement such as a nutraceutical may be an alternative route to the consumption of functional ingredients with health benefits. This is particularly valid for phenolic compounds, which are not chemically synthesized and need to be extracted.

Rats fed high-fructose diets exhibit metabolic changes similar to those observed in MetS [25]. In the present study, we used a 65% high fructose diet to induce hypertriglyceridemia in rats, followed by an oral administration of green tea extract (GTE) or microencapsulated green tea extract (MGTE). In addition, we compared the effects of GTE and MGTE on lipid metabolism and cardiovascular tissue in hypertriglyceridemic rats.

Materials and Methods

Preparation of GTE and MGTE

GTE was obtained from Bioland Ltd. (Cheonan, Chungnam, Korea). The GTE contained 98% catechins, comprising 6 major ingredients including epicatechin gallated catechins, epicatechins, epigallocatechins gallates, galocatechins gallates, and epicatechin gallates.

MGTE was prepared as follows: GTE was added into deionized water and maltodextrin (1:4, v/v) and then force-dispersed by

hydroshear homogenizer (Janke & Kunkel, IKA[®] Labortechnik, Staufen, Germany) at 8,000 rpm for 30 min. Thereafter, the MGTE was dried by using a freezing dryer (SFD6M24L, Samwon Freezing Engineering Co., Seongnam, Korea).

Experimental animals and diets

A total of 40 male Wistar rats, 8 weeks of age, with an initial body weight of 247.2 ± 1.8 g (Orient-Bio laboratory Animal Research Center Co., Ltd., Seongnam, Korea) at the start of the experiment, were housed in individual stainless steel wire cages, in an animal room under constant conditions (12 h light-dark cycle, a temperature of 22 ± 1 °C, and a relative humidity of $50 \pm 5\%$). They had free access to food and drinking water. After a week of acclimation, the rats were randomly divided into 2 groups and fed either the AIN-93 diet (normal control group, NCON, $n = 10$) or the modified AIN-93 diet in which cornstarch was substituted with 65% fructose to induce hypertriglyceridemia, for 8 weeks [26]. Hypertriglyceridemia was defined as serum TG level > 200 mg/dL [27] by a LipidoCare Biosensor (MedicalSK, Inc., Daegu, Korea). Subsequently, the hypertriglyceridemic rats were randomly divided into 3 subgroups ($n = 10$ each) according to the serum TG levels. The 2 groups of rats were fed every day for 4 weeks either with GTE (hypertriglyceridemic GTE, HGTE) or with MGTE (hypertriglyceridemic microencapsulated GTE, HMGT) dissolved in distilled water using an oral Zonde needle (Natsume, Japan). In previous studies, the intake levels of GTE ranged from 50 to 120 mg $\text{kg}\cdot\text{bw}^{-1} \cdot \text{d}^{-1}$ [28,29]. In the present study, the daily dose of GTE or MGTE was set at 50 mg $\cdot \text{kg}\cdot\text{bw}^{-1} \cdot \text{d}^{-1}$. The rats in the normal control group and in 1 high fructose fed group (hypertriglyceridemic control, HCON) were fed with equal volume of distilled water. The ingredients used in this study were as follows: casein (Daejung Chemical and Metal Co., Gyeonggi-do, Korea); cellulose, mineral mix, and vitamin mix (G-Bio Co., Gyeonggi-do, Korea); cornstarch (Daesang Co., Seoul, Korea); sucrose (Samyang Co., Ulsan, Korea); fructose (Tate and Lyle, Decatur, IL, US); soybean oil (Cheiljedang Co., Seoul, Korea); and choline bitartrate and *tert*-butylhydroquinone (Sigma Aldrich, St. Louis, MO, USA). The animal experiments were conducted according to the accepted ethical rules for animal research and were approved by the Animal Ethics Committee of Kookmin University (Permission No. 201202).

Postprandial blood sampling and TG measurement

At the beginning and after the 8-week period on high fructose or normal control diet, food was removed from the rats at 09:00 am. At 14:00 pm, a fasting blood sample (20 μL) was obtained by tail-tipping and blood TG was measured using a LipidoCare Biosensor (MedicalSK, Inc., Daegu, Korea).

Blood and tissue sample processing

After 12 weeks of the experimental period, the rats were sacrificed following 16 h of starvation, by decapitation. The liver, heart, epididymal, and retroperitoneal fat pads were removed quickly, weighed, and stored at -70°C until biochemical analysis. Blood samples were collected and centrifuged at 3,000 rpm at 4°C for 15 min, and the supernatants were stored at -70°C for biochemical analysis.

Biochemical analysis

The levels of TG, total cholesterol (TC), and HDL-C in the serum were measured by the enzymatic colorimetric method using commercial ASAN Reagents assay kits (Asanpharm Co., Gyeonggi-do, Korea).

The serum concentration of non-esterified free fatty acids (NEFA) and uric acid (UA) were analyzed using a commercial assay kit (EFFA-100; Bio-Assays Systems, CA, USA, UA; ASAN UA-Lq Reagent, Asanpharm Co., Korea) according to the manufacturer's instructions.

Enzyme activity analysis

The liver and retroperitoneal fat pads were homogenized in 0.25 M sucrose/Tris-HCl (0.01 M, pH 8) with a homogenizer (OMNI-INC, Marietta, USA), as described previously [30]. The homogenates were centrifuged at $40,000 \times g$ for 10 min, and the supernatants were used to analyze enzyme activity. The assay medium for malic enzyme (ME) consisted of 100 mM Tris buffer (pH 7.4), 100 μL of 100 mM sodium malate, 50 μL of 20 mM, NADP^+ , and 0.75 mL of 20 mM MnCl_2 . The final volume of the assay mixtures was 3 mL in all cases. Enzyme activity was evaluated according to the increase in NADPH produced by the reaction catalyzed by malic enzyme [30]. The protein content of tissues was quantified by the SMART BCA Protein Assay Kit (21071; Intronbio, Korea)

Catalase activity was analyzed spectrophotometrically as described by Beers and Sizer [31]. The liver and kidney (0.4 g each) were homogenized with 1.6 mL of 50 mM phosphate buffer (pH 7.0). The homogenates were centrifuged at 10,000 rpm for 30 min, and then 2 mL of the supernatant was allowed to react with 1 mL of 30% hydrogen peroxide (H_2O_2). The decrease of 30% H_2O_2 in the presence of tissue homogenate was measured at 240 nm after 2 min.

Histomorphometric analysis

Heart tissue was fixed in 10% phosphate-buffered formalin for 1 day and processed in a routine manner to generate 5- μm -thick paraffin sections. Sections were stained with Masson-Trichrome staining and examined microscopically. Approximately 10 randomly selected fields of each heart sections were observed with a light

microscope at $100 \times$ magnification. The occurrence of myocardial fibrosis was examined in each heart section and the percentage estimated for every field. Myocardium thickness and lumen diameter of the left ventricle (LV) were measured with a ruler, and images were captured at $400 \times$ magnification on a flat computer monitor. Five randomly selected images of the LV from each heart were used for measuring myocardial thickness and the diameter of LV was measured at the largest and the smallest part.

Statistical analysis

All data were analyzed using the statistical package for the social science (SPSS, version 20). One-way analysis of variance (ANOVA) was performed, and Duncan's multiple range test was used to determine the significance of differences among the groups. A *P* value of < 0.05 was considered statistically significant.

Results

Body weight, food intake and organ weight

The body weight, daily food intake, and organ weights are presented in Table 1. High fructose diet did not affect food intake. While feeding high fructose diet increased final body weight (407.7 g vs 429.8 g), GTE treatment suppressed the increase of final body weight over 4 week study. Although the significant difference between final body weights of HGTE and HMGT groups was not observed, the effect of GTE on body weight gain tended to be lower compared to that of MGTE treated rats. The administration of GTE reduced food intake in HGTE group significantly ($P < 0.05$), but the MGTE did not.

Significant liver weight increases were observed in high fructose fed rats with the mean increase in absolute liver weight of high fructose fed rats compared with controls being 40%. The administration of GTE and MGTE also produced statistically significant decreases in the weights of epididymal fat and retroperitoneal fat pad in high fructose fed rats.

Table 1. Body weight, food intake and organ weight in experimental groups (g)

Group	NCON ¹⁾	HCON	HGTE	HMGT
Initial body weight	249.9 \pm 3.4 ^{NS2)}	244.9 \pm 4.7	248.3 \pm 3.8	245.5 \pm 3.0
Body weight at 8 week	343.4 \pm 11.4 ^{NS}	346.3 \pm 9.2	348.9 \pm 7.1	329.4 \pm 9.2
Final body weight	407.7 \pm 16.7 ^{ab}	429.8 \pm 10.2 ^b	378.1 \pm 10.9 ^a	373.9 \pm 7.4 ^a
Weight gain	44.3 \pm 4.2 ^{ab}	83.5 \pm 3.8 ^b	29.1 \pm 9.8 ^a	44.6 \pm 5.8 ^{ab}
Daily food intake	33.3 \pm 0.8 ^b	31.8 \pm 0.9 ^b	27.3 \pm 1.5 ^a	32.1 \pm 1.7 ^b
Liver weight	9.9 \pm 0.9 ^a	12.9 \pm 2.4 ^b	9.6 \pm 1.5 ^a	10.5 \pm 1.6 ^a
Epididymal fat pad	6.5 \pm 1.5 ^b	7.3 \pm 2.2 ^b	3.2 \pm 1.3 ^a	3.9 \pm 1.9 ^a
Retroperitoneal fat pad	6.6 \pm 3.4 ^{bc}	8.0 \pm 3.5 ^c	3.6 \pm 1.9 ^a	3.8 \pm 2.20 ^{ab}

¹⁾ NCON: normal diet control, HCON: 65% fructose diet control, HGTE: 65% fructose diet +50 mg/kg green tea extract, HMGT: 65% fructose diet +50 mg/kg microencapsulated green tea extract.

²⁾ Values are expressed as the mean \pm SEM, n=10 rats per group, NS, not significant. Different letters in a same row indicate significantly different values assessed by Duncan's multiple test ($P < 0.05$).

Blood profiles

The initial mean postprandial serum TG concentration in the high fructose control diet-fed rats before GTE or MGTE treatment was 219.8 ± 77.5 mg/dL. Fig. 1 illustrates the changes in postprandial serum TG levels over a 4-week period of high fructose diet and high fructose diet with GTE or MGTE treatment. Fructose-fed rats had a higher serum TG level ($P < 0.05$) than normal control diet-fed rats and it remained elevated for the remainder of the 4-week experimental period. The administration of GTE or MGTE in high fructose-fed rats reduced postprandial blood TG significantly ($P < 0.05$). However, there was no significant difference in the postprandial blood TG responses to the GTE or MGTE treatment.

Table 2 summarizes the effect of GTE and MGTE treatment on fasting serum TC, HDL-C, NEFA, and uric acid concentrations. High fructose-fed rats had higher fasting serum TC levels ($P < 0.05$) than normal control diet-fed rats. GTE and MGTE administration in high fructose-fed rats decreased TC levels over the 4-week treatment period. However, there was no significant difference between the GTE and MGTE treated groups.




Fig. 1. The changes of postprandial serum triglyceride concentrations in experimental groups. NCON: normal diet control, HCON: 65% fructose diet control, HGTE: 65% fructose diet +50 mg/kg bw green tea extract, HMGT: 65% fructose diet +50 mg/kg bw microencapsulated green tea extract. Different letters indicate significantly different values assessed by Duncan's multiple test ($P < 0.05$).

Table 2. Serum parameters in experimental groups

	Total cholesterol (mg/dL)	HDL-C ²⁾ (mg/dl)	NEFA (mg/dl)	Uric acid (μ g/dL)
NCON ¹⁾	66.1 ± 3.2^{a3}	32.7 ± 2.2^a	796.9 ± 79.9^b	551.3 ± 16.7^{ab}
HCON	94.4 ± 4.6^c	56.4 ± 2.2^c	780.5 ± 44.5^b	648.3 ± 26.1^c
HGTE	80.3 ± 3.6^b	45.1 ± 1.8^b	605.8 ± 39.3^a	538.9 ± 32.3^{ab}
HMGT	85.6 ± 5.8^{bc}	46.3 ± 3.5^b	521.5 ± 41.9^a	518.0 ± 26.8^a

¹⁾ NCON: normal diet control, HCON: 65% fructose diet control, HGTE: 65% fructose diet +50 mg/kg bw green tea extract, HMGT: 65% fructose diet +50 mg/kg bw microencapsulated green tea extract.

²⁾ HDL-C, HDL cholesterol; NEFA, non esterified fatty acid.

³⁾ Values are expressed as the mean \pm SEM, $n = 10$ rats per group. Different letters in a same column indicate significantly different values assessed by Duncan's multiple test ($P < 0.05$).

The HDL-C level was higher in the high fructose fed rats and decreased after GTE or MGTE treatment. Serum NEFA levels were significantly higher in the normal diet fed and the high fructose fed groups than in the HGTE and MGTE groups. GTE treatment reduced blood NEFA concentrations and MGTE treated rats had the lowest level of NEFA.

Enzyme activities

The activities of ME, which regulates lipogenesis in the liver and fat tissue, are presented in Table 3. The activity of ME in the liver was significantly greater in rats fed a high fructose diet than in rats fed a normal control diet. The activities of ME in the liver (NCON group, 53.4 ± 4.8 ; HCON group, 94.6 ± 5.1 ; HGTE group, 101.3 ± 3.4 ; HMGT group, 102.8 ± 4.0 mU/mg protein) did not differ among high fructose-fed groups irrespective of treatment with GTE. The activities of ME in the retroperitoneal fat tissue did not differ among the experimental groups.

The activity of catalase, which reduces the oxidative status, was significantly decreased in high fructose-fed rats (Table 3). The administration of GTE or MGTE increased the activity of catalase. The activity of hepatic catalase in the MGTE treated group was significantly higher than that in the GTE treated group. Renal catalase activity was not significantly different between the experimental groups, although a tendency towards a reduction of catalase activity was observed in the high fructose-fed groups.

Table 3. Enzyme activities of tissues in experimental groups

	Hepatic ME ²⁾ (mU/mg protein)	Perirenal ME (mU/mg protein)	Hepatic catalase (U/mg protein)	Renal catalase (U/mg protein)
NCON ¹⁾	53.4 ± 4.8^{a3}	49.8 ± 5.4^{NS}	357.8 ± 18.3^{bc}	422.3 ± 47.5^{NS}
HCON	94.6 ± 5.1^b	56.5 ± 7.4	216.3 ± 32.5^a	366.3 ± 74.1
HGTE	101.3 ± 3.4^b	47.7 ± 3.5	311.1 ± 20.7^b	360.2 ± 10.3
HMGT	102.8 ± 4.0^b	43.5 ± 4.1	385.6 ± 5.8^c	381.8 ± 17.5

¹⁾ NCON: normal diet control, HCON: 65% fructose diet control, HGTE: 65% fructose diet +50 mg/kg bw green tea extract, HMGT: 65% fructose diet +50 mg/kg bw microencapsulated green tea extract.

²⁾ ME, malic enzyme.

³⁾ Values are expressed as the mean \pm SEM, $n = 10$ rats per group, NS, not significant. Different letters in a same column indicate significantly different values assessed by Duncan's multiple test ($P < 0.05$).

Table 4. The histopathologic changes in experimental groups

	Myocardial fibrosis (%)	LV thickness ²⁾ (mm)	LV diameter I (mm)	LV diameter II (mm)
NCON ¹⁾	2.5 ± 0.74^{a3}	2.8 ± 0.1^a	5.2 ± 0.4^{NS}	3.0 ± 0.5^{NS}
HCON	5.8 ± 0.6^{bc}	3.1 ± 0.1^b	5.8 ± 0.3	3.4 ± 0.4
HGTE	6.7 ± 0.8^c	3.4 ± 0.2^b	6.6 ± 0.4	3.6 ± 0.3
HMGT	4.0 ± 1.1^{ab}	3.2 ± 0.2^b	6.2 ± 0.6	3.4 ± 0.2

¹⁾ NCON: normal diet control, HCON: 65% fructose diet control, HGTE: 65% fructose diet +50 mg/kg bw green tea extract, HMGT: 65% fructose diet +50 mg/kg bw microencapsulated green tea extract.

²⁾ LV: left ventricle, LV diameter I: the largest luminal diameter of LV, LV diameter II: the smallest luminal diameter of LV.

³⁾ Values are expressed as the mean \pm SEM, $n = 10$ rats per group, NS, not significant. Different letters in a same column indicate significantly different values assessed by Duncan's multiple test ($P < 0.05$).




Fig. 2. Histological images of myocardial fibrosis. A, B, C, and D: Masson-Trichrome stained sections of myocardium. Images captured at 400 × magnification. A: normal control rat, B: high fructose control rat, C: high fructose plus green tea extract, D: high fructose plus microencapsulated green tea extract.

Cardiac histopathology

Myocardial fibrosis was observed in the heart as shown in Table 4 and Fig. 2. The high fructose diets significantly increased the fibrosis compared to normal control diets ($P < 0.001$). The administration of MGTE, but not GTE, significantly decreased myocardial fibrosis in HGTE rats (Table 4 and Fig. 2). The presence of myocardial fibrosis in the HMGT group was reduced to the level in normal control rats. The mean LV thickness and LV luminal diameters were not significantly different among the experimental groups.

Discussion

This study examined the effect of non-encapsulated and microencapsulated green tea extract in rats fed a high fructose diet. Feeding high fructose for 8 weeks induced the development of several features of MetS. First, in rats fed a high fructose diet, serum TG, TC, and uric acid levels increased compared to that in those given normal control diet. These data are in agreement with several previous reports [32-34]. Bantle *et al.* [35] suggested that the effect of dietary fructose on blood TG is greater in the postprandial state than in the fasting state. In our study, postprandial blood TG increased $> 100\%$ in rats fed a high fructose diet compared to rats fed normal control diet. Hypertriglyceridemia due to high fructose intake has been attributed to an overproduction of lipid in the liver. The enhanced hepatic TG was related to overproduction of TG and decreased TG clearance [36]. In addition, the increased intake of fructose has been reported to enhance oxidative damage in rats [37]. In the present study, the high fructose diet might have increased the level of oxidative stress by decreasing catalase activities in the liver and kidney. Second, high fructose diet increased blood TC

concentrations, body weight gain, and retroperitoneal fat mass.

Administration of $50 \text{ mg} \cdot \text{kg} \cdot \text{bw}^{-1} \cdot \text{d}^{-1}$ GTE to rats with hypertriglyceridemia lowered the level of serum TG. Beneficial changes in serum TC levels were observed in both GTE and MGTE treated groups. GTE treatment decreased serum NEFA levels, resulting in normalization of serum TG (Table 2). The hypertriglyceridemia reported previously is likely related to increased de novo lipogenesis in combination with an increased NEFA flux into the liver [38,39]. Because the NEFA of adipocytes drain into the portal vein, they are delivered to the liver thereby stimulating gluconeogenesis, increasing TG synthesis, and ultimately resulting in the development of dyslipidemia [39]. GTE treatment decreased visceral obesity by decreasing the weight of visceral fat pad (epididymal and retroperitoneal fat pad). In addition, GTE treatment might be responsible for the observed reduction of serum NEFA levels in the HGTE and MGTE groups (Tables 1 and 2). In a previous study, catechin-rich GTE had an anti-obesity effect by elevating the metabolic rate and fat oxidation through lipolysis in adipose tissue [28]. In our study, MGTE treatment was associated with the lowest level of serum NEFA among all the experimental groups. However, there was no significant difference between serum TG and TC between the HGTE and MGTE groups. The malic enzyme, one of the lipogenic enzymes of liver and retroperitoneal tissue, was not affected by treatment with GTE or MGTE. This finding suggests that GTE might have a suppressive effect on hypertriglyceridemia by increasing lipid oxidation, rather than by decreasing the lipogenic enzyme activity. Unexpectedly, we observed an increase in HDL cholesterol in the HCON, HGTE, and MGTE groups. Elevated HDL-C levels are probably caused by increased cholesterol efflux from the peripheral and/or liver cells.

There is supporting evidence that uric acid may have a pathogenic role in the development of MetS. Hyperuricemia has been reported to predict the development of obesity and hypertriglyceridemia [25]. Nakagawa *et al.* [25] and other study reported that lowering the levels of uric acid improved some features of the MetS including hypertension, obesity, and hypertriglyceridemia [40]. In the present study, GTE prevented and reversed the features of MetS in fructose-fed rats. Microencapsulated GTE lowered the level of serum uric acid to a greater extent than GTE. It has been suggested that increased serum uric acid might induce the overproduction of hepatic TG and reduction of TG clearance through the decrease in lipoprotein lipase activity in endothelial cells [25]. In addition, uric acid could play a pathogenic role in fructose-mediated MetS by reducing endothelial NO bioavailability both in cell culture and in experimental models [40].

The present study provides additional information on the damaging effect of high fructose diet on the cardiovascular system by increasing myocardial fibrosis. Myocardial fibrosis, LV thickness, and LV diameter characterize the morphologic changes in rats and are gross indicators of cardiomyopathy [41]. Myocardial fibrosis is one of the main structural pathologic

changes that develop over time in normal and obese animals [42], and has been associated with concurrent decrease in left ventricular compliance and varying degrees of ventricular hypertrophy [41]. Because the contribution of cardiovascular disease to human morbidity and mortality is very high in the elderly, much research in this area has been directed towards determining the role of specific food components on the development, progression, and prevention of CVD [4-9]. Our results demonstrate that MGTE treatment effectively prevents myocardial fibrosis together with a reduction in blood TG and TC levels. Recently, we demonstrated that microencapsulated GTE reduced the inflammatory response by decreasing NO production in murine RAW264.7 cells [43]. It is generally believed that catechin derivatives are the active components responsible for the beneficial effects of antioxidant [13] and cardioprotectants [44]. Oxidants are involved in the pathogenesis of dyslipidemia and CVD [12]. Therefore, the beneficial effects of antioxidants may be attributed, in part, to the lowering of oxidant levels. However, bioactive ingredients including polyphenols are degraded during processing and storage (temperature, oxygen, and light) and under the conditions encountered in the gastrointestinal tract (pH, enzyme, and interactions with other nutrient) [16]. The effectiveness of nutraceutical products in preventing various diseases depends on preserving the bioavailability of the bioactive ingredients. It has been reported that only a small proportion of the ingredients remain available following oral administration due to insufficient gastric residence time, low permeability, and/or solubility within the gastrointestinal tract [45]. In addition, Lambert *et al.* [46] found that polyphenols in green tea oxidize readily in beverages and even in the oral cavity, generating substantial levels of H₂O₂, which is potentially cytotoxic. Some bioactives are particularly susceptible to oxidation; therefore, microencapsulation of bioactives has the ability to preserve them in certain environments [47]. Lee *et al.* [48] found that microencapsulation of GTE with maltodextrin increased DPPH radical scavenging activities. Reineccius *et al.* [49] enhanced the retention of orange oil and prevented the oxidation by using gum Arabic. In our experiments, the beneficial effect of microencapsulated GTE was demonstrated by the reduction of serum uric acid and myocardial fibrosis and the increase in liver catalase activity compared to non-encapsulated GTE. Thus, the protection of bioactives from oxidation could be an effective way to utilize their beneficial effects on human health.

This work compared the ability of GTE and microencapsulated GTE to ameliorate hypertriglyceridemia and mediate cardiovascular protection. According to our results, microencapsulated GTE is more effective at alleviating the cardiovascular risk induced by high fructose feeding than non-encapsulated GTE.

References

1. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;24:683-9.
2. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med* 2003;163:427-36.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143-421.
4. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. *Arterioscler Thromb Vasc Biol* 2004;24:e19-24.
5. Austin MA. Plasma triglyceride and coronary heart disease. *Arterioscler Thromb* 1991;11:2-14.
6. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. *Am J Cardiol* 1998;81:7B-12B.
7. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *JAMA* 1996;276:882-8.
8. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. *Circulation* 1997;95:69-75.
9. Shankar A, Mitchell P, Rohtchina E, Wang JJ. The association between circulating white blood cell count, triglyceride level and cardiovascular and all-cause mortality: population-based cohort study. *Atherosclerosis* 2007;192:177-83.
10. Dauchet L, Montaye M, Ruidavets JB, Arveiler D, Kee F, Bingham A, Ferrières J, Haas B, Evans A, Ducimetière P, Amouyel P, Dallongeville J. Association between the frequency of fruit and vegetable consumption and cardiovascular disease in male smokers and non-smokers. *Eur J Clin Nutr* 2010;64:578-86.
11. Genkinger JM, Platz EA, Hoffman SC, Comstock GW, Helzlsouer KJ. Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. *Am J Epidemiol* 2004;160:1223-33.
12. Greenlee H. Natural products for cancer prevention. *Semin Oncol Nurs* 2012;28:29-44.
13. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. *J Nutr* 2003;133:3275S-3284S.
14. Ebrahimzadeh MA, Nabavi SM, Nabavi SF. Correlation between the in vitro iron chelating activity and poly phenol and flavonoid contents of some medicinal plants. *Pak J Biol Sci* 2009;12:934-8.
15. Tuñón MJ, García-Mediavilla MV, Sánchez-Campos S, González-Gallego J. Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. *Curr Drug Metab* 2009;10:256-71.

1. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality

16. Yue X, Xu Z. Changes of anthocyanins, anthocyanidins, and antioxidant activity in bilberry extract during dry heating. *J Food Sci* 2008;73:C494-9.
17. Kumamoto M, Sonda T, Nagayama K, Tabata M. Effects of pH and metal ions on antioxidative activities of catechins. *Biosci Biotechnol Biochem* 2001;65:126-32.
18. Chen Z, Zhu QY, Tsang D, Huang Y. Degradation of green tea catechins in tea drinks. *J Agric Food Chem* 2001;49:477-82.
19. Rodriguez-Saona LE, Giusti MM, Wrolstad RE. Color and pigment stability of red radish and red-fleshed potato anthocyanins in juice model systems. *J Food Sci* 1999;64:451-6.
20. Moyer RA, Hummer KE, Finn CE, Frei B, Wrolstad RE. Anthocyanins, phenolics, and antioxidant capacity in diverse small fruits: vaccinium, rubus, and ribes. *J Agric Food Chem* 2002;50:519-25.
21. Cai YZ, Corke H. Production and properties of spray-dried amaranthus betacyanin pigments. *J Food Sci* 2000;65:1248-52.
22. Ersus S, Yurdagel U. Microencapsulation of anthocyanin pigments of black carrot (*Daucus carota* L.) by spray drier. *J Food Eng* 2007;80:805-12.
23. Augustin MA, Hemar Y. Nano- and micro-structured assemblies for encapsulation of food ingredients. *Chem Soc Rev* 2009;38:902-12.
24. Augustin MA, Abeywardena MY, Patten G, Head R, Lockett T, De Luca A, Sanguansri L. Effects of microencapsulation on the gastrointestinal transit and tissue distribution of a bioactive mixture of fish oil, tributyrin and resveratrol. *J Funct Foods* 2011;3:25-37.
25. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ. A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* 2006;290:F625-31.
26. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. *J Nutr* 1993;123:1939-51.
27. Ueno T, Tremblay J, Kunes J, Zicha J, Dobesova Z, Pausova Z, Deng AY, Sun YL, Jacob HJ, Hamet P. Rat model of familial combined hyperlipidemia as a result of comparative mapping. *Physiol Genomics* 2004;17:38-47.
28. Zheng G, Sayama K, Okubo T, Juneja LR, Oguni I. Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. *In Vivo* 2004;18:55-62.
29. Lin JK, Lin-Shiau SY. Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. *Mol Nutr Food Res* 2006;50:211-7.
30. Wise EM Jr, Ball EG. Malic enzyme and lipogenesis. *Proc Natl Acad Sci U S A* 1964;52:1255-63.
31. Beers RF Jr, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. *J Biol Chem* 1952;195:133-40.
32. Busserolles J, Gueux E, Rock E, Demigné C, Mazur A, Rayssiguier Y. Oligofructose protects against the hypertriglyceridemic and pro-oxidative effects of a high fructose diet in rats. *J Nutr* 2003;133:1903-8.
33. Hininger-Favier I, Benaraba R, Coves S, Anderson RA, Roussel AM. Green tea extract decreases oxidative stress and improves insulin sensitivity in an animal model of insulin resistance, the fructose-fed rat. *J Am Coll Nutr* 2009;28:355-61.
34. Thresher JS, Podolin DA, Wei Y, Mazzeo RS, Pagliassotti MJ. Comparison of the effects of sucrose and fructose on insulin action and glucose tolerance. *Am J Physiol Regul Integr Comp Physiol* 2000;279:R1334-40.
35. Bantle JP, Raatz SK, Thomas W, Georgopoulos A. Effects of dietary fructose on plasma lipids in healthy subjects. *Am J Clin Nutr* 2000;72:1128-34.
36. Mayes PA. Intermediary metabolism of fructose. *Am J Clin Nutr* 1993;58:754S-765S.
37. Busserolles J, Rock E, Gueux E, Mazur A, Grolier P, Rayssiguier Y. Short-term consumption of a high-sucrose diet has a pro-oxidant effect in rats. *Br J Nutr* 2002;87:337-42.
38. Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, Giacca A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. *Am J Physiol Endocrinol Metab* 2003;284:E863-73.
39. Yang LY, Kuksis A, Myher JJ, Steiner G. Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from [2H₆]ethanol. *J Lipid Res* 1996;37:262-74.
40. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005;67:1739-42.
41. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariéty J, Michel JB. Colocalization of myocardial fibrosis and inflammatory cells in rats. *Lab Invest* 1994;70:286-94.
42. Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, Reddy AK, Taffet G, Michael LH, Entman ML, Ballantyne CM. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. *Am J Physiol Heart Circ Physiol* 2006;291:H2504-14.
43. Jun YK, Kim MH, Seong PN, Chang MJ. A comparison of anti-inflammatory activities of green tea and grapefruit seed extract with those of microencapsulated extracts. *Korean J Nutr* 2012;45:443-51.
44. Yanagi S, Matsumura K, Marui A, Morishima M, Hyon SH, Ikeda T, Sakata R. Oral pretreatment with a green tea polyphenol for cardioprotection against ischemia-reperfusion injury in an isolated rat heart model. *J Thorac Cardiovasc Surg* 2011;141:511-7.
45. Bell LN. Stability testing of nutraceuticals and functional foods. In: Wildman RE, editor. *Handbook of Nutraceuticals and Functional Foods*. Boca Raton (FL): CRC Press; 2001. p.501-16.
46. Lambert JD, Kwon SJ, Hong J, Yang CS. Salivary hydrogen peroxide produced by holding or chewing green tea in the oral cavity. *Free Radic Res* 2007;41:850-3.
47. Champagne CP, Fustier P. Microencapsulation for the improved delivery of bioactive compounds into foods. *Curr Opin Biotechnol* 2007;18:184-90.
48. Lee HD, Kim HS, Seong PN, Kim MH. Effect of microencapsulation procession on functional property of natural pigment and antioxidant. *Food Eng Prog* 2012;16:283-6.
49. Reineccius GA, Ward FM, Whorton C, Andon SA. Developments in gum acacias for the encapsulation of flavors. In: Risch SJ, Reineccius GA, editors. *Encapsulation and Controlled Release of Food Ingredients*. Washington, D.C.: ACS Publications; 1995 p.161-8.